LOREBACT 1.5g
The combination of Ceftriaxone (3 rd generation cephalosporin) and Sulbactam
(beta-lactamase inhibitor) provides a solution for treatment of such bacterial
infections caused betalactam resistant pathogens.
Ceftriaxone has a broad spectrum of antibacterial activity is beta-lactamase stable
and exhibits excellent activity against Streptococcus pneumonia, methicillin-
susceptible staphylococci, Haemophilus influenza, Moraxella catarrhalis and
Neisseria spp which are the most common cause of community acquired and
hospital acquired infections.
Sulbactam is a penicillanic acid sulfone derivative and has weak antibacterial
activity, but is a potent inhibitor of many plasmid-encoded and some chromosomal
beta-lactamases.It therefore restores antibacterial activity of cephalosporins and
penicillins which can be destroyed by beta-lactamases and ESBL’s commonly
produced by gram-positive and gram-negative organisms.
Contraindication
Lorebact 1.5g inj is contraindicated in patients with known allergy to penicillins
and cephalosporins.
Warnings
Serious or occasionally fatal anaphylactic reactions have been reported in patients
receiving beta-lactam antibiotics.These reactions are more likely to occur in
individuals with a history of hypersensitivity reactions to multiple allergens.
Pseudomembranous colitis has been reported with the use of cephalosporins (and
other broad spectrum antibiotics), therefore it is important to consider its diagnosis
in patients who develop diarrhea in association with antibiotic use.
© Copyright 2025. All Rights Reserved.